Ensuring Patient Access and Effective Drug Enforcement Act of 2016

Bill: 114-s-483
Sponsor: Sen. Hatch, Orrin G. [R-UT]
Introduced: 2015-02-12 in the Senate
Policy area: Crime and Law Enforcement
Subjects: Administrative remedies
Congressional oversight
Crime prevention
Criminal investigation, prosecution, interrogation
Department of Justice
Drug trafficking and controlled substances
Government information and archives
Government studies and investigations
Health care coverage and access
Licensing and registrations
Medical education
Prescription drugs
Retail and wholesale trades

Summary:
action_date: 2015-02-12
text: 

Ensuring Patient Access and Effective Drug Enforcement Act of 2015

 
 Amends the Controlled Substances Act to define: (1) "factors as may be relevant to and consistent with the public health and safety," for purposes of the Attorney General's determination of whether registering an applicant to manufacture or distribute a controlled substance in schedule I or II is in the public interest, as factors that are relevant to and consistent with the findings of such Act; and (2) "imminent danger to the public health or safety," for purposes of the suspension of such a registration, to mean that in the absence of an immediate suspension order, controlled substances will continue to be distributed or dispensed by a registrant who knows or should know, through fulfilling the obligations of the registrant under such Act, that the dispensing is outside the usual course of professional practice, that the distribution or dispensing poses a present or foreseeable risk of adverse health consequences or death due to the abuse or misuse of the controlled substances, or that the controlled substances will continue to be diverted outside of legitimate distribution channels.
 
Requires an order to show cause as to why such a registration should not be denied, revoked, or suspended to: (1) contain a statement of the basis for the denial, revocation, or suspension, including specific citations to any laws or regulations alleged to be violated; (2) direct the applicant or registrant to appear before the Attorney General at a specific place and time within 30 days after receipt of the order; and (3) notify the applicant or registrant of the opportunity to submit a corrective action plan on or before such appearance. Requires the Attorney General, upon review of any such plan, to determine whether denial, revocation, or suspension proceedings should be discontinued or deferred for purposes of modifications to such plan. Makes such requirements inapplicable to the issuance of an immediate suspension order.
 
Directs the Department of Health and Human Services, acting through the Food and Drug Administration and the Centers for Disease Control and Prevention, to submit a report identifying: (1) obstacles to legitimate patient access to controlled substances; (2) issues with diversion of controlled substances; and (3) how collaboration between federal, state, local, and tribal law enforcement agencies and the pharmaceutical industry can benefit patients and prevent diversion and abuse of controlled substances.

action_date: 2016-02-11
text: 

Ensuring Patient Access and Effective Drug Enforcement Act of 2016

 
(Sec. 2) This bill amends the Controlled Substances Act to define phrases related to the Drug Enforcement Administration's (DEA's) authority to register manufacturers, distributors, and dispensers of controlled substances.
 
Currently, the DEA registers a controlled substances manufacturer, distributor, or dispenser if it is in the public interest after considering certain factors, including factors relevant to and consistent with the public health and safety. This bill defines "factors as may be relevant to and consistent with the public health and safety" to mean factors relevant to and consistent with the specified purposes of the Controlled Substances Act.
 
Additionally, current law allows the DEA to immediately suspend a registration to prevent imminent danger to the public health and safety. This bill defines "imminent danger to the public health and safety" to mean an immediate threat of death, serious bodily harm, or abuse of a controlled substance due to a registrant's failure to maintain effective controls against diversion.
 
The bill revises and expands the required elements of an order to show cause issued by the DEA before it denies, revokes, or suspends a registration for a Controlled Substances Act violation. An order to show cause must specifically state the legal basis for the action and notify the registrant of the opportunity to submit a corrective action plan. 
 
(Sec. 3) The Food and Drug Administration, the Substance Abuse and Mental Health Services Administration, the Agency for Research and Quality, and the Centers for Disease Control and Prevention, in coordination with the DEA, must report to Congress on:
 
 
obstacles to legitimate patient access to controlled substances; 
 
diversion of controlled substances; 
 
how collaboration between law enforcement agencies and the pharmaceutical industry can benefit patients and prevent diversion and abuse of controlled substances; 
 
the availability of and gaps in medical education, training opportunities, and comprehensive clinical guidance for pain management and opioid prescribing; 
 
enhancements to prescription drug monitoring programs; and 
 
improvements to prescription opioid reporting requirements.
 

action_date: 2016-04-19
text: 
(This measure has not been amended since it was reported to the Senate on February 11, 2016. The summary of that version is repeated here.)
 

Ensuring Patient Access and Effective Drug Enforcement Act of 2016

 
(Sec. 2) This bill amends the Controlled Substances Act to define phrases related to the Drug Enforcement Administration's (DEA's) authority to register manufacturers, distributors, and dispensers of controlled substances.
 
Currently, the DEA registers a controlled substances manufacturer, distributor, or dispenser if it is in the public interest after considering certain factors, including factors relevant to and consistent with the public health and safety. This bill defines "factors as may be relevant to and consistent with the public health and safety" to mean factors relevant to and consistent with the specified purposes of the Controlled Substances Act.
 
Additionally, current law allows the DEA to immediately suspend a registration to prevent imminent danger to the public health and safety. This bill defines "imminent danger to the public health and safety" to mean an immediate threat of death, serious bodily harm, or abuse of a controlled substance due to a registrant's failure to maintain effective controls against diversion.
 
The bill revises and expands the required elements of an order to show cause issued by the DEA before it denies, revokes, or suspends a registration for a Controlled Substances Act violation. An order to show cause must specifically state the legal basis for the action and notify the registrant of the opportunity to submit a corrective action plan. 
 
(Sec. 3) The Food and Drug Administration, the Substance Abuse and Mental Health Services Administration, the Agency for Research and Quality, and the Centers for Disease Control and Prevention, in coordination with the DEA, must report to Congress on:
 
 
obstacles to legitimate patient access to controlled substances; 
 
diversion of controlled substances; 
 
how collaboration between law enforcement agencies and the pharmaceutical industry can benefit patients and prevent diversion and abuse of controlled substances; 
 
the availability of and gaps in medical education, training opportunities, and comprehensive clinical guidance for pain management and opioid prescribing; 
 
enhancements to prescription drug monitoring programs; and 
 
improvements to prescription opioid reporting requirements.
 


Legislative actions:
action_date: 2016-04-19
text: Became Public Law No: 114-145.
action_date: 2016-04-19
text: Became Public Law No: 114-145.
action_date: 2016-04-19
text: Signed by President.
action_date: 2016-04-19
text: Signed by President.
action_date: 2016-04-14
text: Presented to President.
action_date: 2016-04-14
text: Presented to President.
action_date: 2016-04-12
text: Motion to reconsider laid on the table Agreed to without objection.
action_date: 2016-04-12
text: On passage Passed without objection. (text: CR H1618-1619)
action_date: 2016-04-12
text: Passed/agreed to in House: On passage Passed without objection.(text: CR H1618-1619)
action_date: 2016-04-12
text: Considered by unanimous consent. (consideration: CR H1618-1619)
action_date: 2016-04-12
text: Mr. Lance asked unanimous consent to take from the Speaker's table and consider.
action_date: 2016-03-21
text: Held at the desk.
action_date: 2016-03-21
text: Received in the House.
action_date: 2016-03-18
text: Message on Senate action sent to the House.
action_date: 2016-03-17
text: Passed Senate with an amendment by Unanimous Consent. (consideration: CR S1605-1606; text as passed Senate: CR S1605-1606)
action_date: 2016-03-17
text: Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(consideration: CR S1605-1606; text as passed Senate: CR S1605-1606)
action_date: 2016-02-11
text: Placed on Senate Legislative Calendar under General Orders. Calendar No. 368.
action_date: 2016-02-11
text: Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
action_date: 2016-02-11
text: Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
action_date: 2016-02-11
text: Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
action_date: 2015-02-12
text: Read twice and referred to the Committee on the Judiciary.
action_date: 2015-02-12
text: Introduced in Senate

Enacted as: number: 114-145